Pancreatic cancer remains one of the most challenging cancer types to treat, with limited effective options for patients with advanced disease. But a new update from Can-Fite BioPharma is offering a glimmer of hope for patients and clinicians alike.
What the Phase 2a Trial Found
Can-Fite recently announced positive topline results from its open-label, single-arm Phase 2a study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma who had progressed on prior therapies.
Namodenoson is an oral A3 adenosine receptor agonist developed to target cancer cells while sparing healthy tissue. Key findings from the data cutoff include:
- 35% of enrolled patients remained on Namodenoson therapy at the time of data analysis
- One patient has stayed on treatment for more than 16 months, a notable duration given the aggressive nature of pancreatic cancer
- The drug maintained a manageable safety profile, with no new safety signals identified during the trial
- Early signs of disease control were observed in a subset of participants, aligning with preclinical data on Namodenoson’s anti-tumor activity
Why This Data Matters for Pancreatic Cancer Care
Pancreatic cancer has a 5-year relative survival rate of just 12% across all stages, per the American Cancer Society. For patients with metastatic disease, that rate drops to 3%.
Most standard therapies only extend life by a few months, making long-term disease control extremely rare. The fact that over a third of patients in the Phase 2a trial remained on Namodenoson highlights its potential to offer more durable benefits than existing options.
Namodenoson’s Unique Mechanism of Action
Unlike traditional chemotherapy that attacks all rapidly dividing cells, Namodenoson targets the A3 adenosine receptor, which is overexpressed in pancreatic cancer cells but barely present in healthy tissues.
This targeted approach is designed to slow tumor growth while minimizing the harsh side effects that often force patients to discontinue treatment. That distinction may explain why so many patients in the trial stayed on therapy for extended periods.
What’s Next for Namodenoson’s Development?
Can-Fite noted it is currently in discussions with global health authorities to map out regulatory pathways for further development of Namodenoson in pancreatic cancer.
The company may advance to a larger Phase 2b or pivotal trial pending these discussions, which could accelerate access to the therapy for patients with limited treatment options. No timeline for next-phase trials has been announced yet.
Implications for Patients and Investors
For patients: While this is early-stage data, the 16-month therapy duration for one participant is a promising signal for a cancer type where progression often occurs within weeks of starting treatment.
For investors: Can-Fite’s pipeline update has drawn attention to Namodenoson’s potential beyond its existing indications in liver disease and inflammatory conditions. Positive pancreatic cancer data could expand the drug’s commercial reach significantly.
Conclusion
Positive early-phase data does not guarantee final regulatory approval, but Can-Fite’s Phase 2a results for Namodenoson mark a meaningful step forward in the search for more effective pancreatic cancer treatments.
With 35% of patients still benefiting from therapy and a strong safety profile, the drug is poised to advance through further clinical testing. Stay tuned for updates as Can-Fite shares more details on its regulatory discussions and next-phase trial plans.
Comments are closed, but trackbacks and pingbacks are open.